About Aryasun
Aryasun is a Healthcare company based in Springfield (United States) founded in 2023. Manufacturing and distributing pharmaceutical medicines with a focus on innovation and patient well-being in India. Its Indian entity Aryasun Pharmaceutical Private Limited reported revenue of ₹21.5 Lakh. Aryasun offers products and services including Medicines and Healthcare Collaborations. Its focus areas include Research and Development, Medical Advancements, Healthcare Collaborations and Pharmaceuticals.
Company details
Aryasun Pharmaceutical is recognized as a fastest-growing company in India, where high-quality medicines are provided to enhance global health. Innovation and patient well-being are prioritized through advanced facilities that adhere to strict quality standards, ensuring safe products are delivered. Collaborations with healthcare providers and researchers are employed to drive medical advancements, while a commitment to affordable and accessible healthcare is maintained. Testimonials from customers indicate that health improvements have been achieved through these medications, supporting the companys role in the sector.
- Headquarters Springfield, United States
- SectorsHealthcare
- Email••••••••
- Legal Name Aryasun Pharmaceutical Pvt Ltd
- Date of Incorporation 12 Oct, 2023
- Jurisdiction Mumbai, Maharashtra, India
- Indian entity revenue₹21.5 Lakh
FY 2025 · +1318% YoY
- Indian entity net profit₹62,246
FY 2025 · 3% margin
- Indian entity EBITDA₹1.2 Lakh
FY 2025 · 6% margin
Associated legal entities of Aryasun
Aryasun operates through Aryasun Pharmaceutical Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Aryasun Pharmaceutical Private Limited CIN U21002MH2023PTC411999 | Active | 12 Oct 2023 | Mumbai, Maharashtra | ₹0.2 Cr | 2 | View details |
Products & Services of Aryasun
Aryasun offers a comprehensive portfolio of products and services, including Medicines and Healthcare Collaborations.
High-quality medicines are manufactured and distributed to address various health needs, with a focus on safety and accessibility.
Collaborations with healthcare providers and researchers are undertaken to advance medical solutions and ensure product safety.
Board of directors of Aryasun Pharmaceutical Private Limited (Aryasun)
Aryasun Pharmaceutical Private Limited is the primary company behind Aryasun. The board of Aryasun Pharmaceutical Private Limited currently have 2 directors; the longest-serving is Bhairav Kumar Mishra, appointed in 2023. 5 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Bhairav Kumar Mishra DIN 10351955 | Director | 12 Oct 2023 | 3 yrs | Aryasun Pharmaceutical Private Limited |
| Narayan Mahato DIN 10147114 | Director | 12 Oct 2023 | 3 yrs | Aryasun Pharmaceutical Private Limited |
Financials of Aryasun
Figures of Aryasun Pharmaceutical Private Limited, the primary company behind Aryasun, for FY 2025. Revenue was ₹21.5 Lakh (+1318% year on year). Net profit was ₹62,246 (3% margin). EBITDA was ₹1.2 Lakh (6% margin).
- ₹21.5 LakhRevenue · FY 2025 · +1318% YoY
- ₹62,246Net profit · 3% margin
- ₹1.2 LakhEBITDA · 6% margin
- ₹20 LakhPaid-up capital
Balance sheet, profit and loss, cash flow and ratios of Aryasun Pharmaceutical Private Limited are on its company page.
Detailed financial statements for Aryasun
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Top companies in Clinical Trials & Research Tech
3 companies that operate in the same segment as Aryasun (Clinical Trials & Research Tech) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Genetic services are provided by Colossal's laboratory operations. | 2021 | Austin, Texas, United States | USD 619.8 M | 252 | ||
Research lab engaged in pharmacological measurements on therapeutic protein variants | 2018 | United States | USD 78.19 M | 22 | ||
Medical research labs are provided by GALY for scientific purposes. | 2018 | Boston, Massachusetts, United States | USD 61.59 M | 25 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Aryasun
Aryasun was founded in 2023.
Aryasun is headquartered in Springfield, United States.
The primary company behind Aryasun, Aryasun Pharmaceutical Private Limited, reported revenue of ₹21.5 Lakh for FY 2025, up 1318% year on year.
Aryasun Pharmaceutical is recognized as a fastest-growing company in India, where high-quality medicines are provided to enhance global health. Innovation and patient well-being are prioritized through advanced facilities that adhere to strict quality standards, ensuring safe products are delivered. Collaborations with healthcare providers and researchers are employed to drive medical advancements, while a commitment to affordable and accessible healthcare is maintained. Testimonials from customers indicate that health improvements have been achieved through these medications, supporting the companys role in the sector.
Aryasun offers Medicines and Healthcare Collaborations.
Aryasun operates through Aryasun Pharmaceutical Private Limited.
The legal entities of Aryasun currently have 2 directors, including Bhairav Kumar Mishra, Narayan Mahato.